{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T20:26:45Z","timestamp":1775680005556,"version":"3.50.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.cpcardiol.2008.10.002","type":"journal-article","created":{"date-parts":[[2009,1,8]],"date-time":"2009-01-08T10:40:00Z","timestamp":1231411200000},"page":"51-84","source":"Crossref","is-referenced-by-count":51,"title":["Aldosterone and Cardiovascular Disease"],"prefix":"10.1016","volume":"34","author":[{"given":"Krishna K.","family":"Gaddam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Pimenta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saima","family":"Husain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Calhoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2008.10.002_bib1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0140-6736(52)92427-6","article-title":"The effect of adrenal extract on mineral metabolism","volume":"1","author":"Tait","year":"1952","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0140-6736(52)91551-1","article-title":"Secretion of a salt-retaining hormone by the mammalian adrenal cortex","volume":"2","author":"Simpson","year":"1952","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib3","first-page":"6","article-title":"Primary aldosteronism, a new clinical syndrome","volume":"45","author":"Conn","year":"1955","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib4","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1210\/jc.85.5.1863","article-title":"Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology","volume":"85","author":"Fardella","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/sj.jhh.1001013","article-title":"High prevalence of primary aldosteronism in the Tayside hypertension clinic population","volume":"14","author":"Lim","year":"2000","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","article-title":"Primary aldosteronism and hypertensive disease","volume":"42","author":"Mosso","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib7","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1373\/clinchem.2004.041780","article-title":"Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity","volume":"51","author":"Schwartz","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib8","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0272-6386(01)80117-7","article-title":"Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio","volume":"37","author":"Gallay","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib9","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","article-title":"Hyperaldosteronism among black and white subjects with resistant hypertension","volume":"40","author":"Calhoun","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/sj.jhh.1001554","article-title":"Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region","volume":"17","author":"Strauch","year":"2003","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib11","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","article-title":"Low-renin status in therapy-resistant hypertension: a clue to efficient treatment","volume":"22","author":"Eide","year":"2004","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib12","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2337\/dc07-0031","article-title":"Primary aldosteronism in diabetic subjects with resistant hypertension","volume":"30","author":"Umpierrez","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib13","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1046\/j.1523-1755.2000.00964.x","article-title":"The sgk, an aldosterone-induced gene in mineralocorticoid target cells, regulates the epithelial sodium channel","volume":"57","author":"Naray-Fejes-Toth","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib14","series-title":"Hypertension, A Companion to Brenner and Rector's The Kidney","first-page":"117","article-title":"Aldosterone and mineralocorticoids","author":"Funder","year":"2005"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib15","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.RES.67.6.1355","article-title":"Remodeling of the rat right and left ventricles in experimental hypertension","volume":"67","author":"Brilla","year":"1990","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib16","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium, and myocardial fibrosis","volume":"120","author":"Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib17","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1172\/JCI117269","article-title":"Mineralocorticoids, hypertension, and cardiac fibrosis","volume":"93","author":"Young","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib18","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1210\/en.2002-220120","article-title":"Slective aldosterone blockade prevents angiotensin II\/salt-induced vascular inflammation in the rat heart","volume":"143","author":"Rocha","year":"2002","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.cpcardiol.2008.10.002_bib19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1046\/j.1440-1681.2001.03523.x","article-title":"New perspectives on the role of aldosterone excess in cardiovascular disease","volume":"28","author":"Stowasser","year":"2001","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0922-4106(95)90018-7","article-title":"Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta","volume":"290","author":"Ikeda","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0735-1097(01)01729-6","article-title":"Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression","volume":"39","author":"Bauersachs","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib22","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","article-title":"Mineralocorticoid receptor antagonism in experimental atherosclerosis","volume":"105","author":"Rajagopalan","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib23","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0895-7061(97)00301-4","article-title":"Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension","volume":"10","author":"Blacher","year":"1997","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib24","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1053\/euhj.1998.1099","article-title":"Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients","volume":"19","author":"Duprez","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib25","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/01.HYP.21.6.929","article-title":"Vasodilation to acetylcholine in primary and secondary forms of human hypertension","volume":"21","author":"Taddei","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib26","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib27","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1161\/01.CIR.0000129307.26791.8E","article-title":"Impaired endothelium-dependant flow mediated vasodilation in hypertensive subjects with hyperaldosteronism","volume":"109","author":"Nishizaka","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib28","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/S0735-1097(03)00333-4","article-title":"Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease","volume":"41","author":"Gokce","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib29","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1126\/science.123.3195.503","article-title":"Human arterial hypertension: a state of mild chronic hyperaldosteronism?","volume":"123","author":"Genest","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib31","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.HYP.0000258554.87444.91","article-title":"Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample","volume":"49","author":"Newton-Cheh","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib32","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1161\/01.HYP.0000154364.00763.d5","article-title":"Hypertension and hypertension: ethnic differences","volume":"45","author":"Grim","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib33","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/jama.1965.03090030022005","article-title":"Normokalemic primary aldosteronism: a detectable cause of curable \u201cessential\u201d hypertension","volume":"193","author":"Conn","year":"1965","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib34","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/jama.205.7.497","article-title":"Incidence of primary aldosteronism uncomplicated \u201cessential\u201d hypertension","volume":"205","author":"Fishman","year":"1968","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.cpcardiol.2008.10.002_bib35","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1440-1681.1993.tb01687.x","article-title":"Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers","volume":"20","author":"Gordon","year":"1993","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib36","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1440-1681.1994.tb02519.x","article-title":"High incidence of primary aldosteronism in 199 patients referred with hypertension","volume":"21","author":"Gordon","year":"1994","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib37","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjhyper.2005.06.031","article-title":"Aldosterone and refractory hypertension: a prospective cohort study","volume":"19","author":"Sartori","year":"2006","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","article-title":"The role of spironolactone in the treatment of patients with refractory hypertension","volume":"1","author":"Ouzan","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib39","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib40","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.amjhyper.2005.06.010","article-title":"Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?","volume":"18","author":"Mahmud","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib41","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib42","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1161\/01.HYP.0000179582.42830.1d","article-title":"Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension","volume":"46","author":"Saha","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib43","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1161\/01.HYP.0000154361.47683.d3","article-title":"Weight loss and the renin-angiotensin-aldosterone system","volume":"45","author":"Engeli","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1054\/plef.2002.0414","article-title":"An oxidized derivative of linoleic acid affects aldosterone secretion by adrenal cells in vitro","volume":"67","author":"Goodfriend","year":"2002","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib45","doi-asserted-by":"crossref","first-page":"14211","DOI":"10.1073\/pnas.2336140100","article-title":"Human adipocytes secrete mineralocorticoid-releasing factors","volume":"100","author":"Ehrhart-Bornstein","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib46","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1378\/chest.125.1.112","article-title":"Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea","volume":"25","author":"Calhoun","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib47","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjhyper.2005.01.002","article-title":"Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension","volume":"18","author":"Nishizaka","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib48","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib49","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/archsurg.141.5.497","article-title":"Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome","volume":"141","author":"Nwariaku","year":"2006","journal-title":"Arch Surg"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib50","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib51","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib52","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib53","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib54","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1161\/CIRCULATIONAHA.106.634626","article-title":"High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction","volume":"114","author":"Beygui","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib55","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib56","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0002-9610(64)90252-1","article-title":"Clinical characteristics of primary aldosteronism from an analysis of 145 cases","volume":"107","author":"Conn","year":"1964","journal-title":"Am J Surg"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib57","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/sj.ki.5000284","article-title":"The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population","volume":"69","author":"Irie","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib58","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/bmj.38814.566019.2F","article-title":"Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial","volume":"332","author":"Tonelli","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib59","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/sj.ki.5000378","article-title":"Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample","volume":"69","author":"Fox","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib60","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","article-title":"Renal damage in primary aldosteronism: results of the PAPY study","volume":"48","author":"Rossi","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib61","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1097\/00004872-199512010-00054","article-title":"Albuminuria in untreated patients with primary aldosteronism or essential hypertension","volume":"13","author":"Halimi","year":"1995","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib62","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","article-title":"Long-term renal outcomes in patients with primary aldosteronism","volume":"295","author":"Sechi","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib63","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1681\/ASN.2004100878","article-title":"Relative glomerular hyperfiltration in primary aldosteronism","volume":"16","author":"Ribstein","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib64","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1161\/01.HYP.0000230482.82239.a0","article-title":"Aldosterone, dietary salt, and renal disease","volume":"48","author":"Pimenta","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib65","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.amjmed.2006.03.038","article-title":"Aldosterone blockade: an emerging strategy for abrogating progressive renal disease","volume":"119","author":"Epstein","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib66","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function","volume":"24","author":"van den Meiracker","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib67","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib68","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib69","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib70","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.HYP.0000231338.41548.fc","article-title":"Plasma aldosterone is independently associated with the metabolic syndrome","volume":"48","author":"Bochud","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib71","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/01.HYP.0000253258.36141.c7","article-title":"Association of adrenal steroids with hypertension and the metabolic syndrome in blacks","volume":"49","author":"Kidambi","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib72","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1210\/jc.2005-1733","article-title":"Prevalence and charecteristics of the metabolic syndrome in primary aldosteronism","volume":"91","author":"Fallo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib73","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.amjhyper.2007.03.012","article-title":"Adiponectin and insulin sensitivity in primary aldosteronism","volume":"20","author":"Fallo","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cpcardiol.2008.10.002_bib74","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280608001667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280608001667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T03:08:19Z","timestamp":1558062499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280608001667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S0146280608001667"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2008.10.002","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}